Tumor pretargeting for radioimmunodetection and radioimmunotherapy

Journal of Nuclear Medicine

Volumn 39, Issue 1, 1998, Pages 65-76

  Zhu, Hui ^b   Jain, Rakesh K ^a   Baxter, Laurence T ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Bifunctional antibody hapten; Pharmacokinetic model; Radioimmunodetection; Radioimmunotherapy; Tumor pretargeting

Indexed keywords

BIOTIN I 131; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; STREPTAVIDINYLATED IMMUNOGLOBULIN F(AB')2 FRAGMENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPUTER SIMULATION; DOSE RESPONSE; DOSIMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR SCINTISCANNING;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; BIOTIN; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MICE; MODELS, THEORETICAL; RADIATION DOSAGE; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; STREPTAVIDIN;

EID: 0031907418     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Goldenberg D, Larson S. Radioimmunodetection in cancer identification. J Nucl Med 1992;33:803-814.
2. Goldenberg DM. Introduction to the fifth conference on radioimmunodetection and radioimmunotherapy of cancer. Cancer Res 1995;55(suppl):5708s-5709s.
3. Larson SM. Improving the balance between treatment and diagnosis: a role for radioimmunodetection. Cancer Res 1995;55(suppl):5756s-5758s.
4. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-4484.
5. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051.
6. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-2658.
7. Jain, RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
8. Jain, RK. Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors. Ann Biomed Eng 1996;24:457-473.
9. Sands H. Radiolabeled monoclonal antibodies for cancer therapy and diagnosis: is it really a chimera? J Nucl Med 1992;33:29-32.
10. Goodwin D, Meares C, MaCall M, McTigue M, Chaovapong W. Pretargeting immunoscintigraph of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988;29:226-234.
11. Goodwin D. Tumor pretargeting: almost the bottom line. J Nucl Med 1995;36:876-879.
12. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-1302.
13. Senter PD, Saulnier MG, Schreiber GJ, et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988;85:4842-4846.
14. Senter PD. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 1989;49:5789-5792.
15. Sung C, van Osdol WW, Saga T, Neumann R, Dedrick RL, Weinstein JN. Streptavidin distribution in metastatic tumor pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res 1994;54:2166-2175.
16. 111Indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconj Radiopharm 1989;2:1-13.
17. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 1991;51:6650-6655.
18. van Osdol WW, Sung C, Dedrick R, Weinstein JN. A distributed phamiacokinetic model for two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. J Nucl Med 1993;34:1552-1564.
19. Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990;50:3445-3452.
20. Zhu H, Baxter LT, Jain RK. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies: evaluation using a physiologically based pharmacokinetic model. J Nucl Med 1997;731-741.
21. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to man using a physiologically based pharmacokinetic model. Cancer Res 1995;55:4611-4622.
22. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994;54:1517-1528.
23. Watson EE, Stabin G. Siegel JAMIRD formulation. Med Phys 1993;20:511-514.
24. Dedrick R. Animal scale-up. J Pharmacokinet Biopharm 1973;1:435-461.
25. Fan Y, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-3130.
26. Bradwell AR, Fairweather DS, Dykes PW, Keeling A, Vaughan A, Taylor J. Limiting factors in the localization of tumours with radiolabeled antibodies, Immunol Today 1985;6:163-170.
27. Bradwell AR, Dykes P, Thomas G. Antibody targeting: theoretical considerations. In: Goldenberg DM, ed. Cancer imaging with radiolabeled antibodies. New York: Kluwer Academic Publishers, 1990:11-25.
28. Rockoff SD, Goodenough D, McIntire KR. Theoretical limitations in the immunodiagnostic imaging of cancer with computed tomography and nuclear scanning. Cancer Res 1980;40:3054-3058.
29. Yao Z, Zhang M, Kobayashi H, et al. Improved targeting of radiolabeled Streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through avidin chase. J Nucl Med 1995;36:837-841.
30. Schlom J, Hand PH, Greiner JW, et al. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res 1990;50(suppl):820s-827s.
31. Buchsbaum DJ. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 1995;55(suppl):5729s-5732s.
32. Knox SJ. Overview of studies on experimental radioimmunotherapy. Cancer Res 1995;55(suppl):5832s-5836s.
33. Khaw B, Strauss HW, Narula J. "Magic bullets": from muskets to smart bombs!!! J Nucl Med 1993;34:2264-2268.
34. Hellman S. Principles of radiation therapy. In: Rosenberg SA, Hellman S, De Vito V, ed. Cancer. Philadelphia: J. B. Lippincott, 1992:2490.
35. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-3130.
36. Sung C, van Osdol W. Pharamcokinetic comparison of direct antibody targeting with pretargeting protocols based on Streptavidin-biotin binding. J Nucl Med 1995;36:867-876.
37. Hindmarsh AC. LSODE and LSODI, two new initial value ordinary differential equation solvers. ACM Signum Newsletter 1980;15:10-11.
38. Rippe B, Haraldsson B. Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiol Scand 1987;131: 411-428.
39. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 1994;74:163-219.